Biomics Biopharma (ASX:BBM) Pretax Margin %: % (As of . 20)


What is Biomics Biopharma Pretax Margin %?

Biomics Biopharma ASX:BBM Pretax Margin % is % as of . 20.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Biomics Biopharma's Pre-Tax Income for the six months ended in . 20 was A$0.00 Mil. Biomics Biopharma's Revenue for the six months ended in . 20 was A$0.00 Mil. Therefore, Biomics Biopharma's pretax margin for the quarter that ended in . 20 was %.

The historical rank and industry rank for Biomics Biopharma's Pretax Margin % or its related term are showing as below:


ASX:BBM's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Biomics Biopharma  (ASX:BBM) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Biomics Biopharma Pretax Margin % Related Terms

Biomics Biopharma Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma Pretax Margin % Chart

Biomics Biopharma Annual Data
Trend
Pretax Margin %

Biomics Biopharma Semi-Annual Data
Pretax Margin %

Biomics Biopharma Pretax Margin % Competitor Comparison

For the Biotechnology subindustry, Biomics Biopharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Pretax Margin % falls into.


Biomics Biopharma Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Biomics Biopharma's Pretax Margin for the fiscal year that ended in . 20 is calculated as

Pretax Margin=Pre-Tax Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Biomics Biopharma's Pretax Margin for the quarter that ended in . 20 is calculated as

Pretax Margin=Pre-Tax Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Biomics Biopharma (ASX:BBM) has a Pretax Margin % of % as of . 20. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's Pretax Margin % too high?
Biomics Biopharma's current Pretax Margin % is %.
How does Biomics Biopharma's Pretax Margin % compare to competitors?
Biomics Biopharma's Pretax Margin % of % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current Pretax Margin % of %. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current Pretax Margin % is % as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.